CN104178492B - The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof - Google Patents
The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof Download PDFInfo
- Publication number
- CN104178492B CN104178492B CN201410330202.2A CN201410330202A CN104178492B CN 104178492 B CN104178492 B CN 104178492B CN 201410330202 A CN201410330202 A CN 201410330202A CN 104178492 B CN104178492 B CN 104178492B
- Authority
- CN
- China
- Prior art keywords
- somatomedin
- cell
- sequence
- egf
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 55
- 102000013275 Somatomedins Human genes 0.000 title claims abstract description 55
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 27
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 25
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 25
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims abstract 5
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims abstract 5
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract 5
- 108091026890 Coding region Proteins 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 8
- 238000003501 co-culture Methods 0.000 abstract description 7
- 239000013604 expression vector Substances 0.000 abstract description 7
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- 230000010261 cell growth Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 56
- 101800003838 Epidermal growth factor Proteins 0.000 description 22
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 22
- 229940116977 epidermal growth factor Drugs 0.000 description 21
- 230000012010 growth Effects 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a kind of coded sequence simultaneously expressing tri-kinds of somatomedin of IGF1, EGF and FGF2, utilize the coded sequence that the present invention provides, corresponding expression vector can be built, secrete efficiently and stably by importing cell there are tri-kinds of somatomedin of bioactive IGF1, EGF and FGF2, for the various researchs needing to add these three somatomedin.Compared with traditional various recombinant growth factors of interpolation, solve owing to the lasting consumption of somatomedin is added external source recombinant growth factors and can not stably be maintained the problem of concentration by cell growth, also avoid the expensive shortcoming of extensive stock recombinant growth factors.The expression vector additionally built can select to transfect different cell as required, build various different co-culture of cells system, realize enriching and apply flexibly, it would be desirable to add exogenous growth factors simultaneously and use the job step of co-culture system to be greatly simplified, decreasing cost.
Description
Technical field
The invention belongs to biotechnology, relate to multiple gene and express simultaneously, specifically, relating to one can transcribe same
The sequence of growth factor I GF1, EGF and FGF2 of three kinds of activation that can secrete is encoded on thing.This sequence may be used for building eucaryon
Fibrocyte expression vector, and can express above-mentioned without processing, directly there is work importing after eukaryotic cell Simultaneous Stabilization in cell
Three kinds of somatomedin of property are also secreted into extracellular.
Background technology
In recent years, constantly take along with the effort deeply and obtaining stem cell in every way of stem cell related mechanism research
New achievement, the huge differentiation potential of stem cell is before repairing and show in terms of the regeneration of damaged organ and being widely applied
Scape, the treatment for multiple disease brings hope.Stem cell is the pluripotent cell that a class can carry out self renewal, at certain bar
Can induce differentiation under part as Various Tissues cell type.According to source difference, by analogue body normal point of specific cells
Changing maturation process, stem cell can be induced to differentiate into neurocyte, myocardial cell, various hemocyte, ear cells etc. respectively
The functioning cell of terminal differentiation.The factor affecting stem cell differentiation is a lot, and mechanism is complicated.Stem cell is utilized to carry out disease treatment
Time, need to be effectively directed stem cell and be divided into certain types of functioning cell, and need certain noble cells quantity
And purity, to reach preferable curative effect and to reduce untoward reaction as far as possible.In order to reach this purpose, it usually needs according to circumstances exist
Cultivating system adds various exogenous growth factors.In the somatomedin that all external sources are added, type-1 insulin like growth factor
(IGF1), epidermal growth factor (EGF) and FGF2 (FGF2) are the somatomedin that application is most.These are three years old
Planting somatomedin to use, they are that strong mitogenesis is former, and receptor is widely distributed, can not only maintain thin the most simultaneously
Born of the same parents survive, and promote cell proliferation, also participate in the atomization of various kinds of cell, the activity of regulation cell and function.
It addition, in a lot of oncology studies, the growth of primary tumor cell or cell line needs in the case of also having many
Add above-mentioned somatomedin, when being beneficial to primary tumor cell survival after in vitro, grow and carry out targeted drug research
Detection tumor cell is to corresponding somatomedin or the dependency of receptor.Press down as studied EGF-R ELISA (EGFR) little molecule
Need to add corresponding somatomedin EGF when the effect of preparation and mechanism to carry out Tumor Cell Growth Stimulated, study into fiber growth
Needing to add corresponding somatomedin during the mechanism of action of factor acceptor (FGFR) inhibitor class medicine, to be usually FGF2, research swollen
The spheroid of tumor stem cell properties is formed and is also required in serum-free medium in experiment add two kinds of somatomedin EGF and FGF2.
But owing to this stability in culture fluid of somatomedin was affected by its half-life, and cell grows growth
The demand of the factor is again lasting, and the artificial recombinant growth factors that adds can not stably maintain it to act on, and recombinate growth because of
The price of son own is the most costly.Therefore if able to express activated somatomedin by cytotostatic, then can effectively exist
Incubation stably maintains the concentration of somatomedin.
Therefore can by build can express simultaneously tri-kinds of somatomedin of activated form IGF1, EGF and FGF2 expression vector,
And import in corresponding cell (as set up the engineering cell for co-culture system), obtain Simultaneous Stabilization and express three kinds of growths
The cell line of the factor, for further research, as set up co-culture system with stem cell, utilizing works cell is continual and steady
Secreting three kinds of somatomedin, stem cell breaks up to specific cells in induction；Co-culture with primary tumor cell, maintain its external life
Deposit, grow and breed.
In eukaryotic cell, destination gene expression is mainly transcribed (including transcribing post-treatment) and translation (includes translation
Post-treatment) regulation and control of two levels.At transcriptional level often through using strong promoter (such as CMV promoter) to reach high level
Stable transcribing, and transcript only includes that the mRNA open reading frame of maturation is to avoid the need for extra transcribing post-treatment as far as possible
(affecting the efficiency producing the transcription product being finally available for translation)；Regulation and control in translation skill then include strengthening translates
Begin, pilot protein matter location (signal peptide as needed for secretion) and the same protein as far as possible reducing synthesis for embody function or
Activity and demand to post translational processing
Therefore, we are according to mentality of designing as shown in Figure 1 in the present invention, by IGF1, EGF and FGF2 tri-growth because of
Sub-coded sequence is connected in series, and makes them may be at when cell inner expression on same transcript, the most once transcribes
Express and express three kinds of somatomedin simultaneously；In order to reduce the impact on final protein of the post translational processing efficiency, make growth
Need not process the most active after the synthesis of factor protein matter, we do not use the coded sequence of complete three kind somatomedin, and
It is only to have cloned to comprise activated partial coding sequence after three kinds of somatomedin processing；In order to effectively make the growth of expression
Cytokine secretion is to extracellular, and we have merged human normal immunoglobulin before each somatomedinThe signal peptide of light chain；Due to
Each somatomedin is the absolute coding frame of initiation codon and termination codon, therefore we three coding sequence it
Between plus Internal ribosome entry site (Internal ribosome entry site, IRES), with ensure three growths because of
Son all can be translated into corresponding protein by ribosome identification effectively；In order to improve the efficiency of translation initiation identification, we
Kozak sequence conservative in eukaryotic cell is with the addition of before each somatomedin coded sequence initiation codon.
According to above-mentioned design, we have invented a people simultaneously encoding tri-kinds of activated growth factor of IGF1, EGF and FGF2
Operation arranges, and this sequence may be used for being building up on expression vector further, and by importing in cell, give expression to three kinds simultaneously
There is bioactive somatomedin.
The present invention can be used for various needs provides the research stablizing external source IGF1, EGF and FGF2, includes but are not limited to do
Cell correlational study and tumor correlational study.
Summary of the invention
It is an object of the invention to provide a kind of coded sequence simultaneously expressing tri-kinds of somatomedin of IGF1, EGF and FGF2, tool
Just like the nucleotide sequence shown in SEQ ID No:1.Wherein the 7th to the 14th, the 888th to the 895th and the 1718th
It is Kozak sequence to the 1725th；15th to the 77th, the 896th to the 958th and the 1726th to the 1788th is
Igk signal coding sequence；297th to the 881st and the 1127th to 1711 is IRES sequence；78th to 290 is
Activated form IGF1 coded sequence；959th to the 1120th is activated form EGF coded sequence；1789th to 2256 for living
Change type FGF2 coded sequence.
It is a further object to provide the application of this coded sequence.This coded sequence is used for building eukaryotic expression and carries
Body, after importing cell (such as 293T cell), can with stability and high efficiency express the growth of IGF1, EGF and FGF2 tri-kinds activation because of
Son, for further with various researchs.
The present invention compared with the existing technology has the following advantages and effect:
Utilize the coded sequence that the present invention provides, corresponding expression vector can be built, the most steady by importing cell
Surely secrete and there are tri-kinds of somatomedin of bioactive IGF1, EGF and FGF2, for various need add these three growth because of
The research of son.Compared with traditional various recombinant growth factors of interpolation, solve owing to somatomedin is continued by cell growth
Consume and add external source recombinant growth factors and can not stably maintain the problem of concentration, also avoid extensive stockization restructuring growth
The shortcoming that factor price is expensive.The expression vector additionally built can select to transfect different cell as required, builds various difference
Co-culture of cells system, it is achieved abundant apply flexibly, it would be desirable to add exogenous growth factors simultaneously and employing co-cultures body
The job step of system is greatly simplified, and decreases cost.
Accompanying drawing explanation
Fig. 1 is the design diagram of tri-kinds of coding sequence of IGF1, EGF and FGF2.
Fig. 2 IRES sequence, IgSignal coding sequence and the clone of activated form EGF coded sequence.
The structure of Fig. 3 slow virus carrier and qualification.
Fig. 4 slow virus infection HEK293T cell.
Fig. 5 Western blot detects growth factor expression.
Fig. 6 CCK-8 detects A549 cell proliferation.
Detailed description of the invention
The present invention combines the drawings and specific embodiments and is described further.These embodiments are merely to illustrate, but are not intended to
The present invention.
Embodiment 1:IRES sequence, IgSignal coding sequence, activated form EGF, IGF1 and FGF2 coded sequence gram
Grand with synthesis.
The clone of IRES sequence:
PCR method is used to clone IRES from pIRES2-EGFP plasmid.Primer is respectively
IRES-F(SEQ ID No:2): 5 '-ACTAGTGCCCCTCTCCCTCCCCCC-3 ',
IRES-R(SEQ ID No:3): 5 '-TCTAGA(underscore part is respectively for TGTGGCCATATTATCATCGTG-3 '
For introduceSpeI andXbaI restriction enzyme site).
PCR amplification condition is 94 DEG C of degeneration 5min, then 94 DEG C of degeneration 30sec, 58 DEG C of annealing 30sec, 72 DEG C of extensions
30sec, totally 30 circulations, last 72 DEG C extend 7min.Amplified production (597bp, Fig. 2 A) is reflected by 2% agarose gel electrophoresis
Fixed, and carry out cutting glue recovery according to the QIAquicK Gel Extraction Kit description of QIAGEN.Take 3 μ l and cut glue recovery
Product is connected, at T with pGEM-T Easy Vector4Lower 16 DEG C of DNA ligase effect connects overnight.Connect product to be transformed into
DH5In competent cell, amicillin resistance plate screening is cultivated, picking positive colony, is just identifying through EcoRI enzyme action
Sequence verification after really.
Ig The clone of signal coding sequence:
PCR method is used to clone Ig from pSecTag2A plasmidSignal coding sequence.Primer is respectively Ig-
F(SEQ ID No:4): 5 '-ACT AGT TAG CCA CCA(underscore part is introduce to TGG AGA CAG AC-3 'SpeI restriction enzyme site, italic thickened portion is the Kozak sequence introduced)；Ig-R(SEQ ID No:5): 5 '-GTC ACC
AGT GGA ACC TGG AA-3’.Ibid, amplified fragments size is 77bp(Fig. 2 A to PCR amplification condition), ibid method is cloned also
Sequence verification.
The clone of activated form EGF coded sequence:
Extract the total serum IgE of colorectal cancer cells SW620 with Trizol method, use the reverse transcription reagents M-MLV of Promega company
Reverse Transcriptase reverse transcription synthesis cDNA, then with this cDNA as template, PCR amplifies EGF coded sequence.Draw
Thing is respectively EGF-F(SEQ ID No:6): 5 '-TTCCAGGTTCCACTGGTGACAATAGTGACTCTGAATGTCCCC-3’
(italic thickened portion is the Ig introducedSignal peptide downstream complementary series), EGF-R(SEQ ID No:7): 5 '-TCTAGA TTA(underscore part is introduce to GCGCAGTTCCCACCACTTCA-3 'XbaI restriction enzyme site, italic thickened portion
Termination codon for introducing), ibid, EGF clip size is 188bp(Fig. 2 A to PCR amplification condition), ibid method is cloned and checks order
Checking.
With IgSignal peptide and EGF coding sequence fragment are template, respectively with Ig-F(SEQ ID No:4) and EGF-R
(SEQ ID No:7) is that upstream and downstream primer carries out overhangPCR amplification, and ibid, amplification obtains 245bp Ig to amplification condition
The fragment (Fig. 2 B) of-EGF mesh, ibid method clone PCR products sequence verification.
Activated form IGF1 and the synthesis of FGF2 coded sequence:
With Kozak sequence and IgActivated form IGF1 and the FGF2 sequence of signal coding sequence are direct by company respectively
Synthesis, sequence is as follows:
(296bp, underscore part is respectively introducing to IGF1SpeI andXbaI restriction enzyme site, italic thickened portion is for drawing
The Kozak sequence entered, italic underscore part is the Ig introducedSignal coding sequence) (SEQ ID:8):
5’-ACTAGT TAGCCACC ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTT CCACTGGTGAC GGACCGGAGACGCTCTGCGGGGCTGAGCTGGTGGATGCTCTTCAGTTCGTGTGTGGAGACAGGGGC
TTTTATTTCAACAAGCCCACAGGGTATGGCTCCAGCAGTCGGAGGGCGCCTCAGACAGGCATCGTGGATGAGTGCTG
CTTCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGCTTAATCTAGA-
3’
(551bp, underscore part is respectively introducing to FGF2SpeI andXbaI restriction enzyme site, italic thickened portion is for drawing
The Kozak sequence entered, italic underscore part is the Ig introducedSignal coding sequence) (SEQ ID:9):
5’-ACTAGT TAGCCACC ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTT CCACTGGTGAC GCAGCCGGGAGCATCACCACGCTGCCCGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCGCCC
GGCCACTTCAAGGACCCCAAGCGGCTGTACTGCAAAAACGGGGGCTTCTTCCTGCGCATCCACCCCGACGGCCGAGT
TGACGGGGTCCGGGAGAAGAGCGACCCTCACATCAAGCTACAACTTCAAGCAGAAGAGAGAGGAGTTGTGTCTATCA
AAGGAGTGTGTGCTAACCGTTACCTGGCTATGAAGGAAGATGGAAGATTACTGGCTTCTAAATGTGTTACGGATGAG
TGTTTCTTTTTTGAACGATTGGAATCTAATAACTACAATACTTACCGGTCAAGGAAATACACCAGTTGGTATGTGGC
ACTGAAACGAACTGGGCAGTATAAACTTGGATCCAAAACAGGACCTGGGCAGAAAGCTATACTTTTTCTTCCAATGT
CTGCTAAGAGCTGATAATCTAGA-3’。
Embodiment 2: the structure of Lentiviral
According to the design of Fig. 1, above-mentioned each fragment acquired is sequentially connected with and is cloned into slow virus carrier plasmid
In pLVX-IRES-ZsGreen1, use restriction endonucleaseEcoRI andXbaI double digestion identifies the direction of Insert Fragment, and forward inserts time slice
Duan great little is 8.2kb and 2280bp(Fig. 3), show to successfully construct.The named pLVX-3GF of plasmid being correctly inserted into.
Extract plasmid pLVX-3GF, pMD2G and pSPAX2 with QIAGEN Plasmid Midi Kits, respectively take 10
It is diluted in the DMEM in high glucose that 1ml does not contains antibiotic without serum, softly mixes, add 30 Attractene
Transfection Reagent is in above-mentioned culture medium, and the soft mixing gentle and quiet 20min that puts of rear chamber is to form transfection composite.People
Embryonic kidney HEK293T cell routine is incubated at the culture fluid supernatant of the DMEM in high glucose training virus containing 10% hyclone, with 0.45 μm filter
Device filters, and 4 C save backup.
The expression in HEK293T cell of 3: the three kinds of somatomedin of embodiment
Inoculation HEK293T cell is (culture medium does not contains antibiotic) in 3.5cm culture dish, and after 24h, (cell reaches 70% remittance
Right) suck culture fluid, add 500 and support in base, in 37 C, 5% CO2Saturated humidity incubator in cultivate.1ml is digested
HEK293T cell suspension after Li Xin and 1ml transfection composite join in 10cm culture dish after mixing gently, in 37 C, 5%
CO2Saturated humidity incubator in cultivate, supply culture medium after 6-8 h to 10ml.Respectively after transfection 48 h and 72 h, collect
ContainUpper cleer and peaceful Polybrene(stock solution 10mg/ml containing virion, final concentration 8/ ml), supply cultivation after 6 h
Liquid, changes fresh medium after 24h, after cell continues to cultivate 48h, and fluorescence microscopy Microscopic observation infection conditions (Fig. 4 A), and adopt
The cell gram of the stable infection of green fluorescent protein can be expressed with limiting dilution assay (1 cells/well is inoculated in 96 orifice plates) screening
Grand (Fig. 4 B), by the named HEK293T/3GF of cell clone of stable infection.
The expression of destination protein after utilizing the detection of Western blot method to infect:
Factors check in cell: results HEK293T/3GF cell and the HEK293T compared with control cells being uninfected by, PBS washing is thin
Born of the same parents 3 times, centrifugal collecting cell, add ice pre-cooling lysate (25 mM Tris-HCl, pH 7.6,150 mMNaCl, 1%
NP-40,1% NaTDC, 0.1% SDS, containing proteinase inhibitor C ompleteTM Protease Inhibitor
Cocktail), it is placed in cracking 30min, 15000r/min, 4 ° of C on ice and is centrifuged 15min collection supernatant, try with DC protein quantification
Agent box measures protein concentration, takes 20Total protein carries out transferring film after 20% PAGE gel electrophoresis, and 10% milk room temperature closes 1h
After, it is separately added into EGF, FGF2 and IGF1 4 ° of C overnight incubation of tri-kinds of antibody (1:500).TBST (TBS adds 0.1%Tween20)
Wash film 3 × 10min, add two anti-(1:5000) incubated at room 2h of peroxidase labelling, wash film 3 × 10min, chemiluminescence
Method detection signal.
Factors check in culture fluid: collect HEK293T/3GF cell and the culture fluid of HEK293T compared with control cells being uninfected by
Each 10ml, centrifugal segregation cell debris ,-80 ° of C lyophilizations, it is dissolved in 500 ddH2O, respectively takes 20Carry out 20% SDS-
PAGE, ibid after transferring film, detecting factor is expressed.
Western blot result is as it is shown in figure 5, all detect destination protein EGF respectively (6. between 6 ~ 18 kDa
2 kDa), IGF1 (6kDa) and FGF2 (17.2 kDa), show three kinds of somatomedin of HEK293T/3GF cell successful expression can
Somatomedin is secreted in culture fluid supernatant.
4: three kinds of somatomedin Function detection of embodiment
HEK293T/3GF cell and HEK293T compared with control cells cellar culture are cultivated in the DMEM in high glucose containing 10% hyclone
In base, in 37 C, 5% CO2Saturated humidity incubator in cultivate.Receive after being further cultured for 48h after cell length to 80% degree of converging
Collection supernatant, as conditioned medium.Human lung cancer cell A549's cell is with every hole 1.5 × 104Individual cell is inoculated in 96 orifice plates, experiment
Group addition 50The conditioned medium of HEK293T/3GF cell and 50Fresh containing 10% hyclone 1640 cultivations
Liquid, matched group adds 50The conditioned medium of HEK293T cell and 50Fresh containing 10% hyclone 1640 trainings
Nutrient solution.After continuing to cultivate 48h, every hole adds 10CCK-8 reagent, by microplate reader detects 450nm after hatching 2h in incubator
Absorbance.Using SPSS18. 0 software to carry out statistical analysis, represent with means ± S.E.M., two groups of means compare employing t
Inspection；P < 0.05 thinks that difference is statistically significant.
Result shows, compares with HEK293T collating condition culture fluid, and HEK293T/3GF cell conditioned medium really can
Enough it is obviously promoted the growth of A549 cell, difference statistically significant (P < 0.05), the life of HEK293T/3GF emiocytosis is described
The long factor is strictly somatomedin (Fig. 6) active, that A549 cell can be promoted to grow.
<110>Zhejiang University
<120>a kind of sequence encoding three kinds of activated form somatomedin and application thereof
<160> 9
<210> 1
<211> 2262
<212> DNA
<213>artificial sequence
<220>
<223>sequence of three kinds of activated form somatomedin is encoded
<400> 1
actagttagc caccatggag acagacacac tcctgctatg ggtactgctg ctctgggttc 60
caggttccac tggtgacgga ccggagacgc tctgcggggc tgagctggtg gatgctcttc 120
agttcgtgtg tggagacagg ggcttttatt tcaacaagcc cacagggtat ggctccagca 180
gtcggagggc gcctcagaca ggcatcgtgg atgagtgctg cttccggagc tgtgatctaa 240
ggaggctgga gatgtattgc gcacccctca agcctgccaa gtcagcttaa tctagtgccc 300
ctctccctcc ccccccccta acgttactgg ccgaagccgc ttggaataag gccggtgtgc 360
gtttgtctat atgttatttt ccaccatatt gccgtctttt ggcaatgtga gggcccggaa 420
acctggccct gtcttcttga cgagcattcc taggggtctt tcccctctcg ccaaaggaat 480
gcaaggtctg ttgaatgtcg tgaaggaagc agttcctctg gaagcttctt gaagacaaac 540
aacgtctgta gcgacccttt gcaggcagcg gaacccccca cctggcgaca ggtgcctctg 600
cggccaaaag ccacgtgtat aagatacacc tgcaaaggcg gcacaacccc agtgccacgt 660
tgtgagttgg atagttgtgg aaagagtcaa atggctctcc tcaagcgtat tcaacaaggg 720
gctgaaggat gcccagaagg taccccattg tatgggatct gatctggggc ctcggtgcac 780
atgctttaca tgtgtttagt cgaggttaaa aaaacgtcta ggccccccga accacgggga 840
cgtggttttc ctttgaaaaa cacgatgata atatggccac atctagttag ccaccatgga 900
gacagacaca ctcctgctat gggtactgct gctctgggtt ccaggttcca ctggtgacaa 960
tagtgactct gaatgtcccc tgtcccacga tgggtactgc ctccatgatg gtgtgtgcat 1020
gtatattgaa gcattggaca agtatgcatg caactgtgtt gttggctaca tcggggagcg 1080
atgtcagtac cgagacctga agtggtggga actgcgctaa tctagtgccc ctctccctcc 1140
ccccccccta acgttactgg ccgaagccgc ttggaataag gccggtgtgc gtttgtctat 1200
atgttatttt ccaccatatt gccgtctttt ggcaatgtga gggcccggaa acctggccct 1260
gtcttcttga cgagcattcc taggggtctt tcccctctcg ccaaaggaat gcaaggtctg 1320
ttgaatgtcg tgaaggaagc agttcctctg gaagcttctt gaagacaaac aacgtctgta 1380
gcgacccttt gcaggcagcg gaacccccca cctggcgaca ggtgcctctg cggccaaaag 1440
ccacgtgtat aagatacacc tgcaaaggcg gcacaacccc agtgccacgt tgtgagttgg 1500
atagttgtgg aaagagtcaa atggctctcc tcaagcgtat tcaacaaggg gctgaaggat 1560
gcccagaagg taccccattg tatgggatct gatctggggc ctcggtgcac atgctttaca 1620
tgtgtttagt cgaggttaaa aaaacgtcta ggccccccga accacgggga cgtggttttc 1680
ctttgaaaaa cacgatgata atatggccac atctagttag ccaccatgga gacagacaca 1740
ctcctgctat gggtactgct gctctgggtt ccaggttcca ctggtgacgc agccgggagc 1800
atcaccacgc tgcccgcctt gcccgaggat ggcggcagcg gcgccttccc gcccggccac 1860
ttcaaggacc ccaagcggct gtactgcaaa aacgggggct tcttcctgcg catccacccc 1920
gacggccgag ttgacggggt ccgggagaag agcgaccctc acatcaagct acaacttcaa 1980
gcagaagaga gaggagttgt gtctatcaaa ggagtgtgtg ctaaccgtta cctggctatg 2040
aaggaagatg gaagattact ggcttctaaa tgtgttacgg atgagtgttt cttttttgaa 2100
cgattggaat ctaataacta caatacttac cggtcaagga aatacaccag ttggtatgtg 2160
gcactgaaac gaactgggca gtataaactt ggatccaaaa caggacctgg gcagaaagct 2220
atactttttc ttccaatgtc tgctaagagc tgataatcta ga 2262
<210> 2
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223>IRES amplification upstream primer I RES-F
<400> 2
actagtgccc ctctccctcc cccc 24
<210> 3
<211> 27
<212> DNA
<213>artificial sequence
<220>
<223>downstream primer IRES-R is used in IRES amplification
<400> 3
tctagatgtg gccatattat catcgtg 27
<210> 4
<211> 26
<212> DNA
<213>artificial sequence
<220>
<223>immunoglobulin kappa signal peptide amplification upstream primer I gk-F
<400> 4
actagttagc caccatggag acagac 26
<210> 5
<211> 20
<212> DNA
<213>artificial sequence
<220>
<223>downstream primer Igk-R is used in the amplification of immunoglobulin kappa signal peptide
<400> 5
gtcaccagtg gaacctggaa 20
<210> 6
<211> 42
<212> DNA
<213>artificial sequence
<220>
<223>forward primer EGF-F is used in the amplification of activated form EGF coded sequence
<400> 6
ttccaggttc cactggtgac aatagtgact ctgaatgtcc cc 42
<210> 7
<211> 29
<212> DNA
<213>artificial sequence
<220>
<223>downstream primer EGF-R is used in the amplification of activated form EGF coded sequence
<400> 7
tctagattag cgcagttccc accacttca 29
<210> 8
<211> 296
<212> DNA
<213>artificial sequence
<220>
<223>with the activated form IGF1 sequence of Kozak sequence and Igkappa signal coding sequence
<400> 8
actagttagc caccatggag acagacacac tcctgctatg ggtactgctg ctctgggttc 60
caggttccac tggtgacgga ccggagacgc tctgcggggc tgagctggtg gatgctcttc 120
agttcgtgtg tggagacagg ggcttttatt tcaacaagcc cacagggtat ggctccagca 180
gtcggagggc gcctcagaca ggcatcgtgg atgagtgctg cttccggagc tgtgatctaa 240
ggaggctgga gatgtattgc gcacccctca agcctgccaa gtcagcttaa tctaga 296
<210> 9
<211> 551
<212> DNA
<213>artificial sequence
<220>
<223>with the activated form FGF2 sequence of Kozak sequence and Igkappa signal coding sequence
<400> 9
actagttagc caccatggag acagacacac tcctgctatg ggtactgctg ctctgggttc 60
caggttccac tggtgacgca gccgggagca tcaccacgct gcccgccttg cccgaggatg 120
gcggcagcgg cgccttcccg cccggccact tcaaggaccc caagcggctg tactgcaaaa 180
acgggggctt cttcctgcgc atccaccccg acggccgagt tgacggggtc cgggagaaga 240
gcgaccctca catcaagcta caacttcaag cagaagagag aggagttgtg tctatcaaag 300
gagtgtgtgc taaccgttac ctggctatga aggaagatgg aagattactg gcttctaaat 360
gtgttacgga tgagtgtttc ttttttgaac gattggaatc taataactac aatacttacc 420
ggtcaaggaa atacaccagt tggtatgtgg cactgaaacg aactgggcag tataaacttg 480
gatccaaaac aggacctggg cagaaagcta tactttttct tccaatgtct gctaagagct 540
gataatctag a 551
Claims (2)
1. express a coded sequence for tri-kinds of somatomedin of IGF1, EGF and FGF2, its nucleotide sequence such as SEQ ID simultaneously
Shown in No:1, wherein the 7th to the 14th, the 888th to the 895th and the 1718th are Kozak sequence to the 1725th；The
15 to the 77th, the 896th to the 958th and the 1726th are Igk signal coding sequence to the 1788th；297th
It is IRES sequence to the 881st and the 1127th to 1711；78th to 290 is activated form IGF1 coded sequence；959th
It is activated form EGF coded sequence to the 1120th；1789th to 2256 is activated form FGF2 coded sequence.
Coded sequence the most according to claim 1 is used for building carrier for expression of eukaryon, it is characterised in that for thin at eucaryon
Born of the same parents express tri-kinds of somatomedin of above-mentioned IGF1, EGF and FGF2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410330202.2A CN104178492B (en) | 2014-07-13 | 2014-07-13 | The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410330202.2A CN104178492B (en) | 2014-07-13 | 2014-07-13 | The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104178492A CN104178492A (en) | 2014-12-03 |
| CN104178492B true CN104178492B (en) | 2016-09-14 |
Family
ID=51959839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410330202.2A Active CN104178492B (en) | 2014-07-13 | 2014-07-13 | The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104178492B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102344924A (en) * | 2011-09-16 | 2012-02-08 | 江苏普罗赛生物技术有限公司 | Simple and convenient chemical industrial technology for prokaryotic expression and purification of human epidermal growth factor (EGF) |
| CN102978202A (en) * | 2012-10-10 | 2013-03-20 | 中国农业科学院北京畜牧兽医研究所 | Over-expression vector for muscle specific expression of pig IGF1 gene |
-
2014
- 2014-07-13 CN CN201410330202.2A patent/CN104178492B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104178492A (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103028119B (en) | Application of miR-132 in preparation of medicine for treating Parkinson's disease | |
| CN103756952B (en) | The structure of a kind of Cynoglossus semilaevis ovary cell line and application process | |
| CN104450620A (en) | Recoverable immortalized hepatic cell line carrying double suicide genes and establishing method of recoverable immortalized hepatic cell line | |
| CN104388465A (en) | Application of MDFI in regulation of pig skeletal muscle growth and development | |
| CN110403954A (en) | Application of the inhibitor of LncRNA XLOC_110286 in the drug that preparation promotes angiogenesis | |
| CN104031884B (en) | The protein arginine transmethylase 7 application in cancer cell metastasis | |
| CN104388428B (en) | A kind of double-strand siRNA disturbing hnRNPA2/B1 gene expression and application thereof | |
| CN102453716A (en) | Clone and application of pig skeletal muscle specificity expression gene alpha-actin promoters | |
| CN103937746A (en) | Preparation method for animal transgenic positive single-cell clone | |
| CN104099371A (en) | Application of KAP26.1 gene as exogenous gene introduced into cashmere goat cells and used for improving wool fineness | |
| CN104178492B (en) | The sequence of three kinds of activated form somatomedin of a kind of coding and application thereof | |
| CN105925609A (en) | Marker gene-containing Tet-on induced over-expression recombinant vector and construction method thereof | |
| CN102899293A (en) | Mesenchymal stem cells genetically modified with angiopoietin 1 gene and construction method and application thereof | |
| CN104232643B (en) | RNAi interference fragments, interference carrier, preparation method and applications | |
| CN103215295B (en) | Targeting vector for integrating Lys gene at fixed point of bate-casein locus and cells constructed thereby | |
| CN105586344B (en) | Inhibit siRNA and its application of influenza virus related gene | |
| CN105154471A (en) | Preparation method of liver cells with low expression or no expression of PERV | |
| CN109750000A (en) | Novel animal cell line R6-MEFs method and purposes are prepared using XistTale inhibition transcription factor R6 | |
| CN104059943A (en) | Panx3 gene overexpression red fluorescence lentiviral vector and building method and application thereof | |
| CN106520766A (en) | Seaweed endogenesis constructive promoter and application thereof | |
| CN103122379A (en) | Method for real-time monitoring on gene transfection | |
| CN107018955A (en) | A kind of transgene pig of the type of resisting porcine circovirus 2 | |
| CN103388008A (en) | Ungulate animal cell line for inductively expressing pluripotent maintenance gene and construction thereof | |
| CN104745634A (en) | Method for improving efficiency of expressing foreign protein by using insect baculovirus expression system | |
| CN104745635B (en) | A kind of method of OASL genes in silence DF-1 cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |